An observational study in Acute Mesenteric Ischemia, sponsored by University of Tartu. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-31.
Sponsored by University of Tartu · Observational
This is a prospective, multicentre observational study screening all adult patients admitted to a participating hospital over a 6-month study period (may be adjusted to 4-8 months according to recruitment) and including all patients with suspicion of or confirmed acute mesenteric ischaemia (AMI).
Only admission data and hospital mortality outcome will be collected for patients in whom suspicion of AMI is not confirmed. For patients with confirmed AMI full data collection regarding diagnostics, management and long-term outcome is required.
Investigators aim to recruit 40-50 sites with expected median of 10-20 patients with confirmed AMI per site during the study period (naturally depending on the size of the hospital). The start of the study is planned for Spring 2022.
The aim of the study is to identify the incidence of AMI and its different forms in adult hospitalized patients, and to describe patient characteristics (demographic, clinical and laboratory) at baseline, applied diagnostics and management, as well as outcomes in patients with AMI. An additional aim is to compare the baseline characteristics and outcomes of patients with confirmed AMI to those of patients with suspected AMI in whom the diagnosis was not confirmed.
40 studies on the registry are indexed under Mesenteric Ischemia; 14 are open to participants now.
This study's enrollment of 709 is above the median of 154 across 26 observational studies indexed under Mesenteric Ischemia.
Browse Mesenteric Ischemia studies →University of Tartu is the lead sponsor of 46 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All adult patients admitted to a participating hospital during the study period will be screened to include all patients with suspicion of or confirmed acute mesenteric ischaemia (AMI).
All patients with suspicion of or confirmed AMI are to be included in the study in accordance with local ethics requirements:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All patients with suspected AMI
Exclusion Criteria:
Age \<18 years Consent declined by patient or next of kin Chronic mesenteric ischaemia without an acute event
Patients in whom diagnosis of acute mesenteric ischaemia (AMI) was confirmed. For these patients full data collection is required, including 1-year outcome. Maximum 500 patients in this group.
Other: No intervention
Patients in whom acute mesenteric ischaemia (AMI) was suspected but not confirmed. For these patients minimal data will be collected, only hospital survival as outcome. Maximum 2000 patients in this group.
Other: No intervention
No intervention
Incidence of AMI
Incidence of AMI in hospitalized adult patients in acute care hospitals
Time frame: 6 months
30 days survival of AMI
survival of patients with confirmed AMI
Time frame: 30 days after admission/suspicion of AMI/study inclusion
Proportion of different forms of AMI
Proportion of each form of AMI from all AMI cases
Time frame: 6 months
Time to diagnosis
Time from symptoms to diagnosis
Time frame: through study completion, study duration 6 months
Time to treatment
Time from diagnosis to treatment
Time frame: through study completion, study duration 6 months
Treatment
Surgery, endovascular intervention or palliation
Time frame: through study completion, study duration 6 months
1 year survival
Survival of patients with AMI 1 year after diagnosis
Time frame: 1 year
Quality of life score
EQ-5D-5L (EuroQoL - European Quality of Life ), 5-25 points, the lower score means better outcome
Time frame: 1 year
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Tartu